Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABvac40 in Amnestic Mild Cognitive Impairment or Very Mild Alzheimer's Disease
NCT03461276Phase 2Completed
- Sponsor
- Araclon Biotech
- Start
- Dec 2017
- Primary completion
- Mar 2023
- Modality
- Peptide-based Cancer Vaccines
- Countries
- 4
01
Overview
A Phase 2 trial of ABvac40 in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by Araclon Biotech. Started Dec 2017; status: completed.
02
Drugs
ABvac40
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT03461276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03461276.